Alkermes plc - Ordinary Shares (ALKS) News
Alkermes plc - Ordinary Shares (ALKS)
Today's Latest Price: $22.19 USD
Updated Jan 22 4:00pm
Add ALKS to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 239 in Medical - Pharmaceuticals
See all "A" rated Strong Buy stocks
StocksNews Articles for ALKS
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest ALKS News From Around the Web
Below are the latest news stories about Alkermes plc that investors may wish to consider to help them evaluate ALKS as an investment opportunity.
Bristol Myers' (BMY) Opdivo Label Expansion Gets Priority ReviewBristol Myers' (BMY) sBLA for the label expansion of Opdivo for gastric cancer, gastroesophageal junction cancer or esophageal adenocarcinoma gets priority review. |
Novo Nordisk (NVO) Files for Ozempic's Label Expansion in USNovo Nordisk (NVO) submits a label expansion application to the FDA for the existing marketing authorization for Ozempic to include a new dose of 2.0 mg. |
AstraZeneca's (AZN) Enhertu Gets EU Nod for Breast CancerAstraZeneca's (AZN) Enhertu gets EU approval for metastatic HER2-positive breast cancer patients who have received two or more prior anti-HER2-based regimens. |
Addiction Treatment Market Size, Top Key Players, Latest Trends, Regional Insights and Global Industry Dynamics By 2027 | Alkermes , Allergan, Cipla, GSK, PfizerWhen a person is addicted to a drug and if the person fails to control the urge, they are given addiction control treatment. This condition is concerned with illegal drugs, nicotine, painkillers, and alcohol. Usage of drugs regularly affects the |
Novartis' (NVS) Ligelizumab Gets Breakthrough Therapy StatusNovartis (NVS) gets Breakthrough Therapy designation by the FDA for ligelizumab for the treatment of chronic spontaneous urticaria. |
The Daily Biotech Pulse: Bausch Health Issues Positive Pre-Announcement, Acorda Streamlines OperationsHere's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 12) AbbVie Inc (NYSE: ABBV ) AcelRx Pharmaceuticals Inc (NASDAQ: ACRX ) Aldeyra Therapeutics Inc (NASDAQ: ALDX ) Alkermes Plc (NASDAQ: ALKS ) AtriCure Inc. (NASDAQ: ATRC ) Bioanalytical Systems, Inc. (NASDAQ: BASI ) BIOLASE Inc (NASDAQ: BIOL ) (announced an agreement to expand laser adoption and hands-on training programs in targeted geographies) CareDx Inc (NASDAQ: CDNA ) Celsius Holdings, Inc. (NASDAQ: CELH ) DermTech Inc (NASDAQ: DMTK ) Dyne Therapeutics Inc (NASDAQ: DYN ) Edap Tms SA (NASDAQ: EDAP ) Evelo Biosciences Inc (NASDAQ: EVLO ) EXACT Sciences Corporation (NASDAQ: EXAS ) Eyenovia Inc (NASDAQ: EYEN ) Genetron Holdings Ltd – ADR (NASDAQ... |
Regeneron (REGN), U.S. Government Ink Deal for COVID-19 TreatmentRegeneron (REGN) inks deal with the U.S. government to sell additional 1.25 million doses (an agreement value of up to $2.625 billion) of its COVID-19 antibody cocktail. |
Horizon (HZNP) Provides Preliminary 2020 Financial ResultsHorizon (HZNP) provides 2020 preliminary financial results and updates on its key drugs. |
Ultragenyx (RARE) Presents Preliminary 2020 Revenues & GuidanceUltragenyx (RARE) provides preliminary 2020 Crysvita revenues and 2021 revenue guidance for the same. |
NuCana (NCNA) Looks Good: Stock Adds 5.7% in SessionNuCana (NCNA) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes. |